Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
05/2003
05/27/2003US6569436 Method of using a vaccine
05/27/2003US6569435 Flavivirus and alphavirus recombinant antigen libraries
05/27/2003US6569433 Compounds and methods for the diagnosis and treatment of B. microti infection
05/27/2003US6569422 Genetically engineered cell culture adapted infectious bursal diseases virus (IBDV) mutants
05/27/2003US6569420 Human interferon-ε: a type I interferon
05/27/2003US6569418 Administering HIV antigen in conjunction with a chemokine.
05/27/2003CA2277724C A composition for inducing humoral anergy to an immunogen
05/27/2003CA2273855C Novel feline fc epsilon receptor alpha chain nucleic acid molecules, proteins and uses thereof
05/27/2003CA2158455C Immunogenic chimeras comprising nucleic acid sequences encoding endoplasmic reticulum signal sequence peptides and at least one other peptide and their uses in vaccines and disease treatments
05/27/2003CA2145169C A process for the purification of aqueous extracts containing allergenically active proteins, extracts obtainable according to this process as well as their use
05/27/2003CA2073493C Recombinant marek's disease virus, process for preparing the same and vaccine containing the same
05/22/2003WO2003042388A1 Polypeptide antigen forming a mimetic structure of the gp41 intermediate state
05/22/2003WO2003042387A1 Novel hair keratin-associated proteins
05/22/2003WO2003042370A2 New gene expressed in prostate cancer and methods of use
05/22/2003WO2003042358A2 Methods of using 48149, a human aminopeptidase family member
05/22/2003WO2003042357A2 Enzymes
05/22/2003WO2003042247A2 Modified anti-tnf alpha antibody
05/22/2003WO2003042246A2 Inhibitors of the notch signalling pathway for use in the treatment of cancer
05/22/2003WO2003042244A2 Immunogenic mimetics of multimer proteins with promiscuous t cell epitope inserts
05/22/2003WO2003042243A2 Immunogenic alk (anaplastic lymphoma kinase) peptides
05/22/2003WO2003042240A2 Polypeptides of pseudomonas aeruginosa
05/22/2003WO2003041736A2 Method for the treatment of cardiotoxicity induced by antitumor compounds
05/22/2003WO2003041735A2 Composotion comprising inhibitors of the notch signalling pathway for the modulation of the immune system
05/22/2003WO2003041734A1 Salmonella vaccine
05/22/2003WO2003041732A2 Contraceptive vaccine compositions comprising a peptide or a plurality of peptides encoded by all or part of the exon 1 of a fsh receptor
05/22/2003WO2003041731A2 Method to obtain protection against bystander allergen
05/22/2003WO2003041652A2 Method of using 18080, a human serine carboxypeptidase family member
05/22/2003WO2003041651A2 Allatoin-containing skin cream
05/22/2003WO2003041650A2 Modulation of lir function to treat rheumatoid arthritis
05/22/2003WO2003041637A2 Lyophilized monoclonal antibody compositions
05/22/2003WO2003041560A2 Compounds and methods for treatment and diagnosis of chlamydial infection
05/22/2003WO2003016464A3 Cancer specific oligosaccharide sequences and use thereof
05/22/2003WO2002102987A3 Methods and compositions based on protein interactions with mastermind
05/22/2003WO2002102836A3 Moraxella (branhamella) catarrhalis antigens
05/22/2003WO2002100327A3 Substituted 1-benzazepines and derivatives thereof
05/22/2003WO2002081625A3 Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
05/22/2003WO2002078766A3 Combination therapy
05/22/2003WO2002072754A3 Mva expressing modified hiv envelope, gag, and pol genes
05/22/2003WO2002068653A3 Tri-hybrid melanoma antigen
05/22/2003WO2002058737A3 Multivalent meningococcal polysaccharide-protein conjugate vaccine
05/22/2003WO2002056831A3 Immunogenic proteoliposomes, and uses thereof
05/22/2003WO2002051430A3 Methods of modulating toll-related receptor (trr) signaling
05/22/2003WO2002044168A3 Indole-type inhibitors of p38 kinase
05/22/2003WO2002031180A3 Flea peritrophin nucleic acid molecules, proteins and uses thereof
05/22/2003WO2002022807A3 Dermatophagoides nucleic acid molecules, proteins and uses thereof
05/22/2003WO2001070941A9 An infective endogenous retrovirus in association with demyelinating diseases e.g. multiple sclerosis
05/22/2003WO2001068708A9 Human and humanized fap-alpha-specific antibodies
05/22/2003US20030096954 Nucleotide sequences coding polypeptide for use in the treatment, prevention and diagnosis of cancer and nervous system disorders
05/22/2003US20030096950 A polypeptide comprising the amino acid of an n-terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof
05/22/2003US20030096823 Method for the treatment of cardiotoxicity induced by antitumor compounds
05/22/2003US20030096790 Bacterial antigens for an immunological test for infection of by a Grampositive bacterium; diagnosing infection associated with central venous catheters, prosthetic devices, and cerebrospinal fluid shunts
05/22/2003US20030096783 21132, a human G-protein coupled receptor family member and uses therefor
05/22/2003US20030096779 High molecular weight Dermatophagoides proteins, and nucleic acids encoding them; used to treat and diagnose mite allergies
05/22/2003US20030096765 Aromatic esters; cytotoxic agents; antitumor agents
05/22/2003US20030096756 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
05/22/2003US20030096755 Suppression of inhibitors
05/22/2003US20030096746 Compounds and methods for inhibiting cancer metastasis
05/22/2003US20030096744 Secreted and transmembrane polypeptides and nucleic acids encoding the same
05/22/2003US20030096397 Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
05/22/2003US20030096370 Gram negative bacterial protein for use in the prevention and treatment of bacterial infection
05/22/2003US20030096369 Non-anaphylactogenic IgE vaccines
05/22/2003US20030096368 Nucleotide sequences coding bactericide for use in the treatment and prevention of neisseria infections
05/22/2003US20030096354 Synthetic polypeptide ligand for use in the treatment of cardiovascular, tumor, viral and hypertensive disorders
05/22/2003US20030096352 Nucleotide sequences coding polypeptides for use in the treatment and prevention of viral and bacterial disease
05/22/2003US20030096350 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
05/22/2003US20030096344 Therapeutic agent for use in the diagnosis and treatment of cancer and cell proliferative disorders
05/22/2003US20030096327 Detection of tumor disorder in humans; obtain tissue sample, screen for presence of tumor marker, presence of marker indicates tumor disorder
05/22/2003US20030096312 Novel natrium-calcium exchanger protein
05/22/2003US20030096306 Intrabodies with defined framework that is stable in a reducing environment and applications thereof
05/22/2003US20030096285 Detection of targets for anticarcinogenic agents; obtain tumor cells, determine protein expression pattern, compare to wild type, isolate differentially expessed proteins, use protein as diagnostic tool
05/22/2003US20030096270 Diagnosing respiratory disorder; obtain cells, monitor expression of marker gene, determine sequence, compare to control, detect polymorphism in polypeptide or nucleotide, presence of polymorphism indicates respiratory disorders
05/22/2003US20030096266 Hydrophobic biopolymer for use in the treatment of infections, blood, inflammatory and muscular disorders
05/22/2003US20030096250 Nucleotide sequences coding polypeptide for use in the prevention of bacterial infection of mammals
05/22/2003US20030096238 Compositions and methods relating to gynecologic cancer specific genes
05/22/2003US20030096226 Use of a native epitope for selecting evolved binding members from a library of mutants of a protein capable of binding to said epitope
05/22/2003US20030096225 Recovering preferential protein from library; obtain cell, transform with vector, express vector, isolate preferential protein
05/22/2003US20030095988 Using an optimum dose of the pathogen itself as an antigen to increase pathogen-specific immune responses; especially effective when the treatment phase is followed by an interruption phase ending upon relapse
05/22/2003US20030095987 Recombinant parainfluenza virus expression system and vaccines
05/22/2003US20030095986 Production of a parvovirus vaccine in plants as viral coat protein fusions
05/22/2003US20030095985 Immunogenic conjugates of Gram-negative bacterial autoinducer molecules and antibodies raised against the same
05/22/2003US20030095984 Vaccine against mumps containing a Jeryl-Lynn virus strain
05/22/2003US20030095980 Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
05/22/2003US20030095979 Xn-PeptideL-Xm, where X is Gly, Ala, Val, Leu, Ile, Pro, Phe, Tyr, Trp, Cys, Met, Glu or Asp; and PeptideL is a potentially immunogenic fragment; and a polycationic material; vaccines
05/22/2003US20030095977 Use of fusion proteins, especially scFvSA, as diagnostic markers or as cell specific targeting agents.
05/22/2003US20030095976 Methods to improve immunogenicity of antigens and specificity of antibodies
05/22/2003US20030095975 Especially Al(OH)3; extract may be a tri-terpenoid glycoside
05/22/2003US20030095974 Containing a metabolisable oil; vaccine adjuvants; saponin may be QuilA or derivative thereof, such as QS21; oil may be squalene
05/22/2003US20030095973 Chlamydia antigens and corresponding DNA fragments and uses thereof
05/22/2003US20030095971 Compositions and methods for WT1 specific immunotherapy
05/22/2003US20030095967 BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
05/22/2003US20030095966 Method of blocking tissue destruction by autoreactive T cells
05/22/2003US20030095963 Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restriced differentiation antigen for treatment of B cell lymphoma
05/22/2003US20030095960 Three human transferases, polynucleotides that identify and encode them, expression vectors, host cells, antibodies, agonists, and antagonists.
05/22/2003US20030095957 Activation of dendritic cells to enhance immunity
05/22/2003US20030095955 Provide a balanced selective pressure against emergence of tumor cell variants that would otherwise escape immune detection.
05/22/2003US20030095927 Provides biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect.
05/22/2003US20030095926 Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
05/22/2003US20030095925 For rapid absorption through the oral mucosa, resulting in fast onset of effect.
05/22/2003US20030095890 Irradiating the material, especially combined with a stabilizer for protection from the radiation
05/22/2003CA2784450A1 Polypeptides of pseudomonas aeruginosa
1 ... 1244 1245 1246 1247 1248 1249 1250 1251 1252 1253 1254 1255 1256 1257 1258 1259 1260 1261 1262 1263 1264 ... 1823